ClinicalTrials.gg
RecruitingNCT06205095EMPOWERUpdated Oct 14, 2026

A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD

A Phase 3 interventional study of Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII and Placebo in Von Willebrand Diseases, sponsored by Unity Health Toronto. Recruiting at 2 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Unity Health Toronto · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 14, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial

Read the detailed description

The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial.

For the first treatment period, patients will be randomized to receive either plasma derived von Willebrand factor:Factor VIII (pdVWF:FVIII) concentrate (plus standard of care) or placebo (plus standard of care) for VWD-associated heavy menstrual bleeding for 4 cycles, crossing over to the comparator treatment during the second treatment period. The first treatment period will be followed by a 1 cycle washout period when no study-based treatment will be delivered.

The main purpose of the pilot will be to evaluate viability and feasibility of the trial design, as well as to explore assay sensitivity to inform determination of the primary efficacy outcome for the definitive randomized trial which will evaluate the effect of prophylaxis with pdVWF:FVIII concentrate compared with placebo on HMB in women with VWD. A secondary objective is to conduct a preliminary assessment of the effect on clinical outcomes of 2-3 doses of prophylaxis with pdVWF:FVIII concentrate when provided on the first 4 days of menstruation compared with placebo.

02

Conditions studied

  • Von Willebrand Diseases
03

In context

von Willebrand Diseases

96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.

This study's planned enrollment of 20 is below the median of 25 across 41 interventional studies indexed under von Willebrand Diseases.

Browse von Willebrand Diseases studies →

Lead sponsor

Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient capable of providing ;
  2. Female patients with HMB over the age of 18 years, for whom prophylactic treatment with Wilate® is deemed clinically appropriate according to the medical discretion (based on their expert opinion given consideration of the patient's bleeding history and responsiveness to treatment) of the treating hemostasis-focused physician practicing at a Hemophilia Treatment Center;
  3. Modified PBAC score > 100 at screening;
  4. Patients with a diagnosis of inherited von Willebrand disease (any type);
  5. Stable treatment for HMB and iron deficiency anemia for 3 cycles before entering the study and anticipated to remain unchanged for the duration of the study;
  6. Patients willing to have an infusion administered by a nurse over the course of the study period;
  7. Patients who agree to use only the feminine hygiene products supplied by the sponsor.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with any other known bleeding disorder;
  2. Pregnancy or plans to become pregnant within the duration of the study;
  3. Breastfeeding or plans to breastfeed within the duration of the study;
  4. Known reactions to human plasma-derived products or any ingredient in the formulation;
  5. Known antibodies to VWF or FVIII;
  6. Severe liver disease;
  7. Anticipated initiation of the following: oral, transdermal, injectable, and vaginal ring hormonal ; GnRH analogues; or a hormonal intrauterine device (IUD) within the study period;
  8. Anticipated elective procedure that is expected to require intensive treatment with VWF or FVIII for >10 days during the study period;
  9. Patients with >2 risk factors for VTE (risk factors are determined at discretion of treating physician) or recent history of thrombosis (i.e. within the last year).
  10. Patient concurrently receiving desmopressin (desmopressin cannot be taken concurrently with Wilate®, except for in the context of escalation treatment for excessive bleeding).
  11. Anticipated initiation of any new therapies for the treatment of heavy menstrual bleeding 3 weeks prior to enrollment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    pdVWF:FVIII concentrate (Wilate®) Treatment and Standard Care

    Wilate® at a dose of 30-60 IU VWF:RCo/kg for the two anticipated heaviest days of bleeding every 24-48 hours within the first 4 days of menstruation will be provided. Additional two optional doses 24-48 hours from the last can be provided. A minimum of 2 doses must be provided.

    Drug: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII

  • Placebo comparator
    Placebo and Standard Care

    Patients randomized to the placebo arm will receive intravenous placebo (normal saline) at the same approximate volume and frequency as the study drug.

    Other: Placebo

Interventions

  • DrugLyophilized concentrate of human coagulation von Willebrand Factor and factor VIII

    Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.

    Also known as: Wilate

  • OtherPlacebo

    Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.

06

What researchers measure

Primary outcomes

  1. Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2

    Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2

    Time frame: 2 years

  2. Proportion of participant drop-out at the end of treatment period 1 and 2

    Proportion of participant drop-out at the end of treatment period 1 and 2

    Time frame: 2 years

  3. Proportion of participants with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2

    Proportion of patients with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2

    Time frame: 2 years

  4. Number of participants enrolled in 2 years (i.e. ability to enroll at least 10 participants in 2 years)

    Ability to enroll at least 10 participants in 2 years

    Time frame: 2 years

  5. Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2

    Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2

    Time frame: 2 years

Secondary outcomes

  1. Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period

    Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  2. The proportion of patients who use of rescue therapy at the end of each treatment period

    The proportion of patients who use of rescue therapy (i.e. more than two days of oral tranexamic acid use, additional treatment with Wilate®, additional hormonal therapy for HMB, urgent/emergent gynecological surgery for HMB, treatment with intravenous iron, red blood cell transfusion, or hospital admission for HMB) at the end of each treatment period

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  3. Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles

    Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  4. Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles

    Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  5. Number of days of oral tranexamic acid use

    Number of days of oral tranexamic acid use

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  6. Number of days of Wilate® treatment received

    Number of days of Wilate® treatment received

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  7. Duration of menstruation (measured in days)

    Duration of menstruation (measured in days)

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  8. Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition

    Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  9. Clinically relevant non-major bleed

    Clinically relevant non-major bleed

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  10. Hemoglobin levels (g/L)

    Hemoglobin levels (g/L)

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  11. Ferritin levels (mcg/L)

    Ferritin levels (mcg/L)

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  12. Use of additional hormonal therapy for heavy menstrual bleeding

    Use of additional hormonal therapy for heavy menstrual bleeding

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  13. Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding

    Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  14. Fatigue scores (as measured by the FACIT fatigue scale)

    Fatigue scores (as measured by the FACIT fatigue scale)

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  15. Short Form-12 Scores

    Short Form-12 Scores

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  16. Scores on the individual components of the Short Form-12

    Scores on the individual components of the Short Form-12

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  17. Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)

    Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  18. Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)

    Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  19. Number of hypersensitivity infusion reactions

    Number of hypersensitivity infusion reactions

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  20. Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);

    Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  21. Proportion of participants who development of VWF inhibitors

    Proportion of participants who development of VWF inhibitors

    Time frame: At the end of 8 menstrual cycles (approximately 10 days)

  22. Number of adverse events

    Number of adverse events

    Time frame: 8 cycles

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2024 (actual). Primary completion is estimated for Dec 2027, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2026 → Dec 2027 and completion Sep 2026 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Jan 12, 2024
StartActual
Oct 21, 2024
Primary completionEst.
Dec 2027was Sep 2026
CompletionEst.
Sep 2028was Sep 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Kingston Health Sciences Centre · Kingston, Canada
Oct 14, 2026
Primary completion
Sep 2026→Dec 2027
Oct 14, 2026
Study completion
Sep 2026→Sep 2028
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    1 site added
    Show site
    • Kingston Health Sciences Centre · Kingston, Canada
    Primary completion Sep 2026→Dec 2027
    Study completion Sep 2026→Sep 2028
    + 4 other changes: identifiers, verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06205095
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Oct 21, 2024
Primary completion
Dec 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

St. Michael's Hospital
Contact
empower@unityhealth.to
4168646060

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion